McMillion Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $1.73M | Sell |
27,050
-270
| -1% | -$18.1K | 1.54% | 18 |
|
|
2023
Q1 | $1.89M | Sell |
27,320
-3,506
| -11% | -$247K | 1.79% | 17 |
|
|
2022
Q4 | $2.22M | Sell |
30,826
-880
| -3% | -$66.4K | 2.01% | 14 |
|
|
2022
Q3 | $2.25M | Sell |
31,706
-1,610
| -5% | -$117K | 2.09% | 10 |
|
|
2022
Q2 | $2.56M | Sell |
33,316
-5,817
| -15% | -$443K | 2.13% | 11 |
|
|
2022
Q1 | $2.86M | Sell |
39,133
-3,896
| -9% | -$262K | 1.77% | 14 |
|
|
2021
Q4 | $2.68M | Buy |
43,029
+109
| +0.3% | +$6.39K | 1.45% | 24 |
|
|
2021
Q3 | $2.54M | Sell |
42,920
-520
| -1% | -$34.2K | 1.49% | 24 |
|
|
2021
Q2 | $2.9M | Sell |
43,440
-1,200
| -3% | -$78.2K | 1.58% | 21 |
|
|
2021
Q1 | $2.82M | Buy |
44,640
+562
| +1% | +$35K | 1.65% | 21 |
|
|
2020
Q4 | $2.73M | Sell |
44,078
-153
| -0.3% | -$9.41K | 1.66% | 19 |
|
|
2020
Q3 | $2.67M | Sell |
44,231
-1,510
| -3% | -$90.9K | 2% | 18 |
|
|
2020
Q2 | $2.69M | Sell |
45,741
-15,275
| -25% | -$914K | 1.77% | 17 |
|
|
2020
Q1 | $3.4M | Sell |
61,016
-2,503
| -4% | -$153K | 2.31% | 12 |
|
|
2019
Q4 | $4.08M | Buy |
63,519
+60
| +0.1% | +$3.44K | 1.96% | 15 |
|
|
2019
Q3 | $3.22M | Sell |
63,459
-1,625
| -2% | -$76.4K | 1.71% | 25 |
|
|
2019
Q2 | $2.95M | Sell |
65,084
-1,381
| -2% | -$64.3K | 1.56% | 29 |
|
|
2019
Q1 | $3.17M | Buy |
66,465
+752
| +1% | +$37.5K | 1.72% | 25 |
|
|
2018
Q4 | $3.42M | Buy |
65,713
+1,045
| +2% | +$56.1K | 2.2% | 18 |
|
|
2018
Q3 | $4.01M | Buy |
64,668
+624
| +1% | +$37K | 2.14% | 17 |
|
|
2018
Q2 | $3.54M | Buy |
64,044
+903
| +1% | +$48.8K | 2.01% | 18 |
|
|
2018
Q1 | $3.99M | Buy |
63,141
+160
| +0.3% | +$10.3K | 2.36% | 12 |
|
|
2017
Q4 | $3.86M | Buy |
62,981
+810
| +1% | +$50.7K | 2.32% | 15 |
|
|
2017
Q3 | $3.96M | Sell |
62,171
-690
| -1% | -$40.3K | 2.6% | 10 |
|
|
2017
Q2 | $3.5M | Sell |
62,861
-59
| -0.1% | -$3.21K | 2.34% | 14 |
|
|
2017
Q1 | $3.42M | Sell |
62,920
-1,740
| -3% | -$95.4K | 2.33% | 18 |
|
|
2016
Q4 | $3.78M | Sell |
64,660
-175
| -0.3% | -$9.57K | 2.7% | 14 |
|
|
2016
Q3 | $3.5M | Buy |
64,835
+1,135
| +2% | +$72.9K | 2.62% | 13 |
|
|
2016
Q2 | $4.68M | Sell |
63,700
-1,795
| -3% | -$127K | 3.62% | 5 |
|
|
2016
Q1 | $4.18M | Sell |
65,495
-99
| -0.2% | -$6.24K | 3.1% | 6 |
|
|
2015
Q4 | $4.51M | Sell |
65,594
-1,677
| -2% | -$111K | 3.38% | 5 |
|
|
2015
Q3 | $3.98M | Sell |
67,271
-6,309
| -9% | -$400K | 3.08% | 6 |
|
|
2015
Q2 | $4.9M | Sell |
73,580
-3,910
| -5% | -$258K | 3.05% | 5 |
|
|
2015
Q1 | $5M | Sell |
77,490
-3,083
| -4% | -$193K | 2.98% | 5 |
|
|
2014
Q4 | $4.76M | Sell |
80,573
-30
| -0% | -$1.69K | 2.73% | 10 |
|
|
2014
Q3 | $4.13M | Sell |
80,603
-1,306
| -2% | -$65.2K | 2.42% | 13 |
|
|
2014
Q2 | $3.97M | Sell |
81,909
-934
| -1% | -$46K | 2.3% | 17 |
|
|
2014
Q1 | $4.3M | Sell |
82,843
-1,710
| -2% | -$91K | 2.62% | 12 |
|
|
2013
Q4 | $4.49M | Sell |
84,553
-169
| -0.2% | -$8.61K | 2.73% | 8 |
|
|
2013
Q3 | $3.92M | Sell |
84,722
-1,821
| -2% | -$79.9K | 2.8% | 9 |
|
|
2013
Q2 | $3.87M | Buy |
+86,543
| New | +$3.76M | 2.85% | 12 |
|
Other funds holding BMY
McMillion Capital Management's BMY Position: Q2 2023 in Review
McMillion Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.99% in Q2 2023, selling an estimated $18.1K and leaving 27,050 shares worth $1.73M. The position accounts for 1.54% of the portfolio, ranked #18.
McMillion Capital Management first reported a position in BMY in Q2 2013 and has held it in 41 quarters since. The position peaked at $5M in Q1 2015. 2,481 funds tracked by Wall St. Rank hold BMY as of Q2 2023.
- McMillion Capital Management held 27,050 shares of Bristol-Myers Squibb worth $1.73M as of Q2 2023.
- McMillion Capital Management sold 270 Bristol-Myers Squibb shares in Q2 2023, an estimated $18.1K.
- Bristol-Myers Squibb made up 1.54% of McMillion Capital Management's portfolio in Q2 2023, its #18 holding.
- McMillion Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 41 quarters since.
- McMillion Capital Management's Bristol-Myers Squibb position peaked at $5M in Q1 2015.
- 2,481 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.
Based on McMillion Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.